Over 70 Florida Auctions End Today - Bid Now

Boston Scientific to acquire Bolt Medical for up to $664 million

by Gus Iversen, Editor in Chief | January 16, 2025
Business Affairs Cardiology
Boston Scientific has announced a definitive agreement to acquire Bolt Medical, a developer of laser-based intravascular lithotripsy (IVL) technology for coronary and peripheral artery disease.

The acquisition, valued at approximately $443 million upfront for the 74% stake not already owned, includes potential milestone payments of up to $221 million. Boston Scientific already holds a 26% equity stake in Bolt Medical, having helped establish the company in 2019.

Bolt Medical's IVL technology uses acoustic pressure waves to fracture calcium deposits within arteries, addressing complex calcified arterial disease through a minimally invasive approach. The Bolt IVL system, designed with visible, directional emitters for consistent energy delivery, complements Boston Scientific’s existing cardiovascular offerings.

"Intravascular lithotripsy therapy addresses a significant unmet need for patients with complex calcified arterial disease," said Lance Bates, senior vice president of interventional cardiology therapies at Boston Scientific. "Bolt Medical is developing next-generation technology that aligns well with our portfolio and provides a platform for future innovation."

Bolt Medical has completed clinical trials for its Above the Knee (ATK) and Below the Knee (BTK) systems for peripheral artery disease and received FDA approval in December 2024 to begin a global clinical trial for its coronary IVL system. These results will support future regulatory submissions in the U.S. and Europe.

The transaction, expected to close in the first half of 2025 pending regulatory approvals, is anticipated to be slightly dilutive to Boston Scientific's adjusted earnings per share in 2025, but offset by cost efficiencies. On a GAAP basis, it is expected to be more dilutive due to acquisition-related charges, though Boston Scientific will recognize a one-time gain from its existing equity stake.

The Bolt IVL system remains an investigational device and is not yet cleared for commercial distribution.

You Must Be Logged In To Post A Comment